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a b s t r a c t
Interferon-γ (IFN-γ) recall responses against foot-and-mouth disease virus (FMDV) in FMD vaccinated cattle
are utilized to study T-lymphocyte immunity against this virus. Here, a recall IFN-γ assay based on a
commercial ELISA was set up using 308 samples from naïve and vaccinated cattle. The assay was used to
study cross-reactive responses between different FMDV vaccine strains. Blood samples from cattle immunized
with monovalent vaccines containing A24/Cruzeiro/Brazil/55, A/Argentina/2001 or O1/Campos/Brazil/58
strains were tested using puriﬁed-inactivated FMDV from homologous and heterologous strains. A24/Cruzeiro
was the most efﬁcient IFN-γ inducer in all vaccinated animals, both when included in the vaccine or as
stimulating antigen. We demonstrate that this was mainly due to the structural stability of the whole viral
particle. These results show that IFN-γ production relies on the presence of 140S particles that can maintain
their integrity along the incubation process in vitro, and throughout the vaccine´s shelf-life, when used in vivo.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Foot and mouth disease (FMD) is an acute and highly contagious-
febrile disease affecting all ruminants and cloven-footed animals
(Alexandersen and Mowat, 2005). Its causative agent, the FMD virus
(FMDV), belongs to the Picornaviridae family, being the main member
of the genus Aphtovirus (King et al., 2011). The disease has been a
major cause of economic losses to livestock industries worldwide:
even though fatal cases are usually restricted to young animals and
certain FMDV strains (Alexandersen et al., 2003), infected animals
signiﬁcantly reduce productive performance and international trade of
animals and animal-derived products is severely restricted between
countries with different sanitary status of the disease. The potential of
FMD to disrupt normal social and economic function (Perry and Rich,
2007) has been dramatically demonstrated in the last two decades by
outbreaks occurred in different countries irrespectively of their
economic development (Muroga et al., 2012; Perez et al., 2004;
Thompson et al., 2002; Yang et al., 1999).
Several concerns have progressively favored the use of vaccines
to control FMD outbreaks (Mackay et al., 2004; Poulin and
Christianson, 2006). Vaccination has been successfully applied as
the main control measure for FMD in different South American
countries, in most cases by means of polyvalent oil vaccines
formulated using inactivated virus from strains previously
detected in the region (Saraiva and Darsie, 2004). Good quality
vaccines may prevent the development and transmission of the
disease and decrease the incidence of persistently infected animals
(Anderson et al., 1974; Cox et al., 2006; Orsel et al., 2005).
FMDV structural proteins are highly variable and seven anti-
genically distinct serotypes have been described for this virus
(Knowles and Samuel, 2003). Consequently, protection provided
by FMD vaccines, which is closely related to the induction of
speciﬁc antibody responses (Maradei et al., 2008; Pay and Hingley,
1987), is serotype-speciﬁc and, in numerous examples, very
limited even for strains within the same serotype (Doel, 2003).
Serological assays, such as virus neutralization tests (VNT) and
liquid-phase blocking ELISA (LPB-ELISA), were designed to detect
levels of antibodies against viral capsid proteins and represent a major
tool to predict the immunological and protective status of the animals
and susceptible populations against FMDV (Barnett et al., 2003; Goris
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et al., 2008; Maradei et al., 2008; Pay and Hingley, 1992). Although
generation of adaptive humoral responses after FMDV infection in
cattle showed to be independent of T-cell collaboration (Juleff et al.,
2009; Pega et al., 2013), vaccine-induced antibody responses are
dependent on the collaboration of FMDV-speciﬁc CD4þ lymphocytes
(Carr et al., 2013). However, induction of FMDV-speciﬁc cellular
immune responses has not usually been considered for the evaluation
of vaccine efﬁcacy (Becker, 1994), probably because of the lack of high-
throughput cell-mediated immunity tests.
The induction of IFN-γ recall responses from bovine mononuclear
cells stimulated with inactivated antigens from infectious pathogens
has been largely used as a measure of pre-existing adaptive cellular
immunity against protozoa, bacteria and viruses (Brown et al., 1993;
Lightbody et al., 1998; Woolums et al., 2003). The in vitro assessment
of gamma interferon (IFN-γ) production was developed as a high
throughput test to detect pathogen-speciﬁc cellular immune
responses in cattle (Wood and Rothel, 1994) using whole blood, thus
avoiding the need of preparing cell-suspensions. Cellular responses
against FMDV have also been studied by detection of IFN-γ, showing
correlation with protection against homologous virus challenge in
sheep (Barnett et al., 2004) and cattle (Oh et al., 2012). In contrast,
heterologous anti-FMDV cellular responses in cattle have been
exclusively reported in early studies using lymphoproliferation assays
(Collen et al., 1998; Collen and Doel, 1990).
Here, we adjusted a protocol and its corresponding acceptance
parameters to measure FMDV-speciﬁc anamnesic IFN-γ responses,
using a large number (n¼308) of whole blood samples from naive and
FMD-vaccinated cattle. Homologous and heterologous responses were
evaluated in groups of animals immunized with O1/Campos, A/Arg/01
or A24/Cruzeiro monovalent formulations or tetravalent FMD vaccines
comprising all the above mentioned strains. Our results demonstrated
the existence of cross-reactive intra- and inter-serotypic cellular
responses in FMD-vaccinated cattle. Also, we observed a differential
ability among viral strains to elicit FMDV-speciﬁc IFN-γresponses, both
in vivo and ex-vivo, and related these observations to the particular
stability of the 140S particles. We concluded that the FMDV-speciﬁc
production of IFN-γ is strongly affected by the integrity of the viral
capsids. Although this information should be considered when
detecting FMDV-speciﬁc production for this cytokine, it may also
result relevant to understand the immunogenic capacity of FMD
vaccines and develop strategies to improve it, for homologous and
heterologous immunity.
Results
Set up of FMDV-speciﬁc bovine IFN-γ ELISA
IFN-γ levels measured from whole blood are extremely variable
(Schiller et al., 2009), consequently the application of this assessment
as a diagnostic tool is based on positive and negative validation
parameters and comparative ratios to a non-stimulated aliquot of the
sample (or stimulated with an unrelated antigen). An IFN-γassay
based on a commercial ELISA was set up with 308 whole blood
samples obtained from naïve and vaccinated animals (Table 1) and
incubated with PWM or PBS (Fig. 1). Most of the animals presented
high levels (43,400 pg/ml) of IFN-γproduction after incubation with
PWM and no differences were found between samples from näive
and vaccinated animals (data not shown). These results corroborated
both the viability of the cells and their capacity to secrete this
cytokine. On the contrary, most of the blood samples incubated with
PBS produced very low or undetectable IFN-γ levels (o 1,000 pg/ml),
indicating that there was no signiﬁcant basal secretion of the
cytokine in this assay. Blood samples from non-vaccinated animals
(n¼114), as well as those from FMD-vaccinated cattle (n¼194), did
not produced IFN-γ when neither stimulating antigen nor mitogen
were dispensed, showing that vaccinated animals yield no basal
responses of this cytokine.
Considering the outcome of the test as positive (PWM acti-
vated) or negative (PBS treated), we exercised a ROC analysis to
establish the minimum IFN-γ value obtained after PWM stimula-
tion as to consider the cells viable and capable to produce IFN-γ,
and the maximum value acceptable for PBS treatment as to
exclude non-speciﬁc IFN-γ production (data not shown). These
limits of cell viability and functionality were ﬁxed in 3,200 pg/mL
and lower (speciﬁcity) limit was calculated to be 1,450 pg/mL.
In these conditions, the assay had a sensitivity of 98.7%, and a
speciﬁcity of 97.9%. From then on, all samples were run including
PBS and PWM controls and results from FMD assessment were
considered to be valid when PBS stimulation rendered less than
1,450 pg/mL and PWM more than 3,200 pg/mL.
Using these acceptance parameters, a protocol for FMDV-speciﬁc
bovine IFN-γ ELISA was standardised by testing whole blood samples
from single- or multi-vaccinated animals incubated at 37 1C for 24, 48
or 72 h with PWM, PBS or with 3 different concentrations (10.0,
5.0 and 2.5 μg/ml)of puriﬁed inactivated 140S particles of FMDV O1/
Campos strain. Responses increased along with the stimulating
antigen's concentration (10.0 μg/mL45.0 μg/mL42.0 μg/ml) and
decreased with incubation times; conditions were ﬁnally standardized
using 10 μg/mL of 140S particles-stimulation for 24 h (Suppl. Fig. 1).
With these conditions, blood samples from naïve (pre-immune)
animals (n¼64) showed no reaction to the stimulation with all tested
FMDV strains, while steers immunized with a single dose of the
commercial tetravalent vaccine (30 dpv, n¼8) produced very vigorous
responses against the viral antigens, in some animals with similar
levels to those obtained with PWM (Fig. 2).
Homologous and cross-reactive IFN-γELISA responses in vaccinated
cattle
FMDV-driven recall production of IFN-γ was determined in
peripheral blood from cattle immunized with FMD monovalent
Table 1
Samples used to determine the acceptance parameters of the IFN-γ assay.
Vaccine regimena n dpv PWMb PBSb
Without vaccination 114 – 12,51276,617 3257707
A24/Cruzeiro Monovalent 10 30 16,69775,632 39078
A/Arg/2001 Monovalent 10 30 12,64476,626 390711
A24/CruzeiroþA/Arg/2001 Bivalent 20 30 15,82675,997 39077
O1/Campos Monovalent 70 30 9,71174,968 38271,137
Tetravalent 50 30/120 17,08976,756 231749
Tetravalent (multiple doses) 34 30/120 20,59976,147 2447187
Total 308 13,86677,019 3227695
a All animals were primo-vaccinated unless otherwise indicated.
b PWM¼ pokeweed mitogen; PBS¼phosphate buffer saline. Values are expressed as mean IFN-γ concentrations (pg/mL7standard deviation) induced for samples
incubated for 24 h with PWM (10 μg/mL) or PBS (n¼number of samples; dpv¼days post vaccination)
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vaccines comprising A24/Cruzeiro(10 μg/dose), A/Arg/01(10 μg/
dose) or O1/Campos(20 μg/dose)strains. Whole blood samples
taken at 30 dpv were stimulated withA24/Cruzeiro, A/Arg/01,
C3/Indaial or O1/Campos sucrose-puriﬁed inactivated 140S parti-
cles (Fig. 3). Homologous stimulation was signiﬁcantly higher for
the A24/Cruzeiro strain than for O1/Campos or A/Arg/01 strains
(po0.01). Also, cellular responses were cross-reactive among the
different serotypes, showing a differential pattern of IFN-γ pro-
duction depending on the strain. Although the A24/Cruzeiro
vaccine induced higher IFN-γ levels than the O1/Campos and A/
Arg/01 vaccines when stimulated with heterologous strains (A/
Arg/01 and C3/Indaial strains, respectively) (po0.05), the O1/
Campos and A/Arg/01 vaccines were only signiﬁcantly cross-
reactive against the A24/Cruzeiro antigen (Figs. 3B and C,
respectively).
FMDV-IFN-γ production requires stimulation with whole 140S
particles
The data showed above suggested that the virus strain was
related to the ability for inducing IFN-γproduction. Based on early
reports indicating the differential structural stability among
strains, we explored whether this factor may be related or not to
the FMDV strains’ capacity to stimulate IFN-γ responses.
We ﬁrst addressed if A24/Cruzeiro and O1/Campos particles
have differential stability in physiological conditions. Puriﬁed 140S
particles were kept at 37 1C and capsid stability was evaluated at
different time points by a 15%–45% SDG puriﬁcation protocol
followed by spectrophotometry and ELISA analyses (Fig. 4). Freshly
thawed A24/Cruzeiro FMDV aliquots (time “0 h”) contained most
of the initial viral amount (120 μg) as 140S particles, as indicated
by the presence of coincident peaks of viral RNA (Fig. 4A) and
capsid proteins (Fig. 4C) in the lower fractions of the gradient (3 to
5 mL) as well as by their absence in the upper range of the
gradient (13 to 15 mL). Contrarily, O1/Campos preparations
already had a signiﬁcant fraction of 12S subunits at this same
time, as veriﬁed by the coincident spectrophotometry and ELISA
peaks in the upper fractions of the gradient (13 to 15 mL, Fig. 4B
and D). Following a 2 h incubation period at 37 1C, 140S parti-
cles from the A24/Cruzeiro strain decreased about 26% with
little differences up to 24 h of incubation (Fig. 4E). In contrast,
O1/Campos 140S particles were continuously disassembled along
the experiment, and RNA and capsid protein peaks corresponding
to 12S subunits clearly increased over time (Fig. 4B and D). After
24 h at 37 1C, over 80% of the O1/Campos 140S particles were
broken down into 12S subunits (Fig. 4E).
We next studied if whole viral capsids were more efﬁcient than
12S particles stimulating blood samples to elicit speciﬁc FMDV-
IFN-γ responses. Disrupted capsids were prepared from both
140S puriﬁed preparations by heat treatment, and presence of
12S pentamers was conﬁrmed by sucrose-gradient and antigen-
speciﬁc ELISA (Fig. 5A and B). Protein degradation in these
preparations was assessed by SDS-PAGE (Fig. 4C), showing that
primary structures of the capsid proteins, and thus T-cell epitopes
comprised within them, were not affected by the heat-treatment.
Next, IFN-γ speciﬁc responses against O1/Campos and A24/Cru-
zeiro FMDV strains were determined by incubating whole blood
from9 multi-vaccinated animals with heat-treated and untreated
viral preparations. As it is shown in Fig. 5D, while IFN-γ levels
detected in samples incubated with PBS wells were lower than in
any of the antigen stimulated wells (po0.01), stimulations
induced by whole 140S particles were signiﬁcantly above those
induced by heat-treated virus for both strains (A24/Cruzeiro,
po0.01; O1/Campos, po0.05). These results clearly indicated that
capsid disruption strongly affected recall IFN-γ responses in FMD
vaccinated cattle.
Discussion
Several research lines have investigated the relation between
IFN-γ and immunity against FMDV in natural hosts. Different
publications have related the production of bovine IFN-γ with
innate and antiviral responses to FMDV in vivo (Toka et al., 2011)
and in vitro (Zhang et al., 2002), and antiviral properties of this
cytokine together with type I interferon were also shown in vivo
for swine (Diaz-San Segundo et al., 2010; Moraes et al., 2007).
However, in ruminants most of the effort has been focused on its
use as indicative of FMDV vaccine- or infection-induced adaptive
immunity (Barnett et al., 2003; Carr et al., 2013; Oh et al., 2012;
Parida et al., 2006).
Here, we ﬁrst set up the incubation conditions of bovine blood
samples to measure high-throughput FMDV-speciﬁc IFN-γ produc-
tion, using a commercial ELISA originally developed forMycobacterium
bovis (Wood and Rothel, 1994). Initial validation parameters of the
assay included 308 samples and were associated to the capacity of the
blood cells to produce IFN-γ (PWM-stimulated wells) and to the IFN-γ
synthesised by cells of the innate immune system in a non-speciﬁc
manner (PBS-stimulated wells). These parameters permitted to har-
monize IFN-γ measurements from different samples by discarding
those that do not ﬁt the positive/negative assay parameters, thus
allowing to compare groups/treatments rather than individuals. Once
set up, the assay applied for FMDV antigens rendered negligible
unspeciﬁc responses: neither blood samples from non-vaccinated
animals stimulated with FMDV antigens, nor samples in PBS-
stimulated wells were capable to produce signiﬁcant levels of IFN-γ.
On the other side, blood samples from FMD primo- or multivaccinated
cattle effectively produced IFN-γ after incubation with puriﬁed
inactivated FMDV from homologous strains.
FMDV-speciﬁc IFN-γ responses were also evoked in blood
samples from cattle vaccinated with monovalent formulations and
stimulated with heterologous strains. Only one report measured
heterologous IFN-γ production before and suggested a high degree
of serotype speciﬁcity after FMDV O1Manisa stimulation in blood
samples from A Iran 96 vaccinated cattle, although data was not
shown in the publication (Parida et al., 2006). Cross-reactive T-cell
responses among FMDV strains have been previously observed by
in vitro lymphoproliferation assays in cattle (Collen et al., 1998;
Collen and Doel, 1990) and swine (Saiz et al., 1992) and were mainly
attributed to CD4þ T lymphocytes. T-cell cross-activation among
FMDV strains is expectable since T-cell epitopes, as short and linear
sequences, are more promiscuous than conformational epitopes.
Consequently, stimulating antigens used in most of the FMDV-
speciﬁc lymphoproliferative assays previously published did not
require complex structures (Cartwright et al., 1980; Collen et al.,
1998; Collen and Doel, 1990)
Our ﬁndings on the existence of cross-stimulation among
serotypes are in agreement with the above cited reports. In our
hands, however, A24/Cruzeiro strain activated higher heterologous
IFN-γ responses than the other strains, when used as an ex-vivo
stimulator or as a vaccine antigen. Conversely, FMDV O1/Campos
and A/Arg/01 strains appeared as less effective antigens in both
situations. Interestingly, such differential ability among strains was
not reﬂected in tetravalent formulations, suggesting that cross-
reactivity also takes place in vivo. Since both papers by Collen et al.
(Collen et al., 1998; Collen and Doel, 1990) demonstrated that
there were no signiﬁcant disparities in the homologous and
heterologous lymphoproliferative capacity between A24/Cruzeiro
and O1/Campos strains, we hypothesised that the differences
observed in their ability to induce IFN-γ were not related to their
primary protein sequences. Thus, based on the different capsid
stability reported among FMDV strains, we explored whether
FMDV-speciﬁc IFN-γ production might be affected by the antigen
structure or not. The stability of whole capsids was higher for
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A24/Cruzeiro preparations than for O1/Campos antigens, in accor-
dance with early reports (Doel and Baccarini, 1981). Interestingly,
we found that the ex-vivo production of IFN-γ in FMD-vaccinated
cattle was strongly related to the capsid integrity of the stimulat-
ing FMDV antigen, independently of the strain tested. It is then
possible to hypothesise that the lower thermal stability of the
FMDV O1/Campos capsids compared to the A24/Cruzeiro strain
may explain its reduced ability to elicit IFN-γ synthesis in blood
from FMD-vaccinated cattle, either as an ex-vivo stimulator or as a
vaccine antigen.
The mechanisms behind all these observations are not clear yet.
Preliminary results from our lab using puriﬁed PBMC from FMD-
vaccinated cattle in the presence or absence of autologous serum did
not show an evident correlation between the IFN-γ production and
the existence of antibodies against FMDV in the sample (data not
shown). Moreover, FMD cell-mediated assessments stimulating with
140S particles, were similar when measured by lymphoproliferative
(using puriﬁed PBMC) or IFN-γ responses (using whole blood
samples) (Bucafusco et al., unpublished results). Other variables
which may differentiate the antigen presentation triggered by 140S
and 12S particles are currently under study.
At ﬁrst, our results have a clear methodological impact for the
high-throughput testing of cell-mediated immunity using stimu-
lated plasma, since the ex-vivo FMDV-speciﬁc IFN-γ evaluation
seems to be strongly affected by the structural integrity of the
stimulating antigen. The use of disrupted capsid particles in the
stimulation phase of the assay may lead to false negative results,
especially when using structurally unstable FMDV strains, such as
those from the O or SAT serotypes.
Furthermore, the phenomenon here described may also affect the
in vivo performance of FMD vaccines. Monovalent vaccines from
O1/Campos were less efﬁcient IFN-γ inducers than A24/Cruzeiro
vaccines or tetravalent formulations. Our observations may be linked
to early reports reﬂecting quantitative differences in the antigenicity
of 140S and 12S particles (Cartwright et al., 1982; Doel and Chong,
1982; Rao et al., 1994). The lower neutralizing antibody titres induced
by 12S particles may be obviously related to destruction of neutraliz-
ing epitopes from the 140S to 12S particles. Furthermore, FMDV-
speciﬁc IFN-γ production in vaccinated cattle has been associated to
the activation of antigen-speciﬁc CD4þ T cells (Oh et al., 2012) which
are responsible for supporting antibody neutralising responses (Carr
et al., 2013). Thus, it is also possible to hypothesise that the reduced
ability of the 12S particles to trigger anamnestic FMDV-speciﬁc IFN-γ
responses may also contribute for the lower immunogenic capacity
in FMD vaccines comprising structurally unstable strains. Further for-
purpose experiments are required to explore this hypothesis.
Materials and methods
Virus puriﬁcation
FMDV A24/Cruzeiro/Brazil/55 (A24/Cruzeiro), O1/Campos/Brazil/
58 (O1/Campos), A/Argentina/2001 (A/Arg/01) and C3/Indaial/Brazil/
71 (C3/Indaial) were kindly provided by a local vaccine producer as
inactivated and concentrated preparations from clariﬁed-infected
cell cultures. Puriﬁed particles were obtained by a 15%–45% sucrose
density gradient (SDG) centrifugation method (Barteling and
Meloen, 1974) further optimized in our laboratory (Pega et al., 2013).
Animals, vaccination and sampling
Different groups of bovines were utilized for the experiments
described in this work, totalling 308samples (Table 1). In all cases,
IFN-γ assays were performed over whole blood samples obtained
by jugular venipunction using Vacutainers tubes (BD) containing
heparin. Samples were transported to the laboratory at room
temperature and processed within 8 h after bleeding. All animal
handling procedures were previously approved by the INTA's
Animal Welfare Commission (protocol approval No. 025/2011).
Heterologous reactivity was assessed using blood samples from
cattle immunized (30 dpv) with one dose of a single-emulsion
oil monovalent FMD vaccines were produced by a local vaccine
manufacturer containing 10 μg of A24/Cruzeiro (n¼10), 10 μg of
A/Arg/01 (n¼10), or 20 μg of O1/Campos (n¼30) inactivated
Fig. 1. Assessment of the acceptance parameters of the IFN-γ production assay.
Whole blood samples (n¼308) from FMD-vaccinated and non-vaccinated animals
(see vaccine status, Table 1) were incubated in the presence of PWM (10 μg/mL) or
PBS for 24 h. Collected plasma samples were tested by ELISA Bovigams. Results are
expressed as individual IFN-γ concentrations (pg/mL) estimated using a standard
curve built with recombinant bovine IFN-γ. Horizontal dotted lines indicate cut-off
values for sample acceptance as determined with ROC analysis. Limit for PWM
stimulation43200 pg/mL (upper line); limit for PBS stimulationo1450 pg/mL
(lower line).
Fig. 2. FMDV-speciﬁc IFN-γ responses in naïve and primo-vaccinated cattle. Whole blood samples were stimulated with 10 μg/mL of FMDV O1/Campos (O1C), A24/Cruzeiro
(A24), A/Arg/2001 (A2001) and C3/Indaial (C3I) for 24 h in tetravalent primo-vaccinated animals (A) or naïve cattle (B). Results are expressed as IFN-γ concentrations (pg/mL,
mean7SEM). Samples included in the graph complied the acceptance parametersestablished for PWM and PBS stimulation.
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FMDV. Vaccine payloads were conﬁrmed by disrupting the vaccine
emulsions after a 2 h incubation with an equal volume of chloroform
at 4 1C under constant stirring, followed by centrifugation at 3000 xg
during 15 min at 4 1C. Aqueous phase was then processed by a
15–45% SDG and recovered 140S particles were quantiﬁed as des-
cribed (Barteling and Meloen, 1974). All the remaining vaccinated
Fig. 3. Heterologous IFN-γ responses in FMD vaccinated cattle. IFN-γ responses to O1/Campos (O1C), A24/Cruzeiro (A24), A/Arg/2001 (A2001) and C3/Indaial (C3I) observed
in cattle vaccinated with single-strain formulations 30 days post vaccination. Sample size and composition for each vaccine are indicated in the panel titles. (#) indicates
mean values signiﬁcantly higher than the non-stimulated control (PBS), (n) indicates mean values signiﬁcantly different between A24/Cruzeiro versus O1/Campos
stimulation (po0.05, Mann-Whitney).
Fig. 4. Stability of puriﬁed FMDV A24/Cruzeiro and O1/Campos whole particles. Puriﬁed 140S particles from A24/Cruzeiro (A, C) and O1/Campos (B, D)strains were incubated
for 0, 2, 8 and 24 h at 37 1C. After incubation, puriﬁed FMDV preparations were submitted to sucrose density gradient and resulting fractions were evaluated by
spectrophotometry at 260 nm (viral RNA) (A, B) and by antigen-ELISA (structural proteins) (C, D). Areas under curve between fractions 3 and 7 (mL) in charts A and B
(representing 140 S particle concentration for O1 /Campos and A24/Cruzeiro, respectively) were determined at time 0 h and 140S concentrations for subsequent time points
were expressed as a percentage of this initial value for each virus strain (E).
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animals were immunized in the frame of the ofﬁcial FMD vaccine
campaign using commercially available single oil emulsion tetrava-
lent FMD vaccines including A24/Cruzeiro, O1/Campos, A/Arg/01 and
C3/Indaial strains.
Assays to detect FMDV-speciﬁc IFN-γ production
Experiments to establish the IFN-γ assay's acceptance para-
meters were performed over the entire set of samples, using
whole blood (1.5 ml)from näive (n¼114) or FMD-vaccinated cattle
(n¼164) immunized following different vaccine regimes (Table 1).
Samples were incubated in 24-well sterile cell culture plates
during 24 h at 37 1C with 5% CO2 (Nunc, USA) using Pokeweed
mitogen (PWM, 10 μg/mL) or phosphate buffer saline pH 7.0 (PBS).
Plates were centrifuged for plasma collection and samples were
stored at 20 1C until processing. IFN-γproduced in each well was
analysed using Bovigams ELISA (Prionics) (Gormley et al., 2006),
performed according to manufacturer's speciﬁcations. IFN-γ levels
were expressed as pg/mL of plasma using a standard curve build
with known concentrations of a recombinant bovine IFN-γ (AbD-
Serotec) ranging from 195 to 25,000 pg/ml. This IFN-γ detection
and quantiﬁcation protocol from stimulated plasma samples was
applied for all subsequent experiments. Experiments aimed to set
up the FMD-speciﬁc IFN-γ assays were carried out using whole
blood samples from näive individuals (n¼2) or cattle vaccinated
with single or multiple (n43) doses (n¼4 each group) of a
commercial tetravalent FMD oil vaccine. Blood samples, taken 28
days after the last vaccination, were incubated with PBS, PWM or
puriﬁed inactivated FMDV O1Campos at 2.5, 5 or10 μg/mL (ﬁnal
concentration). Cultures were left for 24, 48 and 72 h at 37 1C with
5% CO2and further processed for IFN-γ detection (results shown in
Supplementary Figure).
Heterologous IFN-γ production was assessed using blood sam-
ples from cattle vaccinated with FMD monovalent formulations
(described in the previous section) and cultured for 24 h (37 1C,
5% CO2) using inactivated puriﬁed FMDV 140S particles from
A24/Cruzeiro, A/Arg/01, O1/Campos or C3/Indaial strains (10 μg/
mL). Finally, assays using whole or disrupted viral particles as
stimulating antigens were performed using blood samples from
9 multivaccinated bovines receiving commercial tetravalent FMD
oil vaccines from the ofﬁcial FMD vaccination campaigns. Condi-
tions of the assay were as described above.
FMDV 140S particle-stability assessment
Inactivated puriﬁed O1/Campos (395 mg/mL) and A24/Cruzeiro
(315 μg/mL) 140S particle preparations stored at 80 1C were
used for this experiment. Five aliquots (120 μg each) of both virus
strains were prepared and frozen at 801C. Each aliquot was then
incubated at 37 1C for 0, 2, 4, 8 and 24 h. After each incubation
time, samples were run in a 15%45% SDG as above. Gradient was
collected in 1 mL fractions and further evaluated by spectro-
photometry at 260 nm (to detect viral RNA) and by an in house
antigen ELISA (to detect FMDV structural proteins). For this ELISA,
fractions were diluted 1:600 in PBS 0.05% Tween 20 (PBST) OVA 1%
and transferred to 96-well ELISA plates (Maxisorp, Nunc) pre-
coated with anti-A24/Cruzeiro or anti-O1/Campos rabbit hyper-
immune sera (1:3000). After 1 h of incubation at 37 1C, plates were
washed 3 times with PBST and captured antigen was detected
using strain-speciﬁc guinea-pig antiserum (1:200) incubated for
1 h at 37 1C. Plates were washed as described above and a
peroxidase-labeled sheep polyclonal anti-guinea-pig antibody
(1:2500, KPL) was added. Finally, after 5 washes with PBST, the
reaction was developed by addition of o-Phenylenediaminedihy-
drochloride/H2O2 in 50 mM phosphate-citrate buffer, pH 5.0. The
Fig. 5. Capacity of 140S and 12S particles to induce recall IFN-γ responses. SDG fractions of FMDV A24/Cruzeiro were heat treated (60 1C, 20 min.) and measured by
(A) spectrophotometry at 260 nm (viral RNA) and (B) by antigen ELISA. Heat treated and non-treated FMDV puriﬁed particles were analyzed in a 12% denaturing SDS-PAGE
and stained with Coomassie blue (C). IFN-γ responses of multi-vaccinated cattle (n¼9) after stimulation with 140 S (O1C, A24) or 12S particles (O1C-HT, A24-HT) from both
strains (D).
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reaction was stopped by the addition of 50 μl of 1.25 M H2SO4 and
OD values were read at 492 nm. Amounts of 140S particles for
each strain at each time-point were calculated as the area under
the curve for a range of fractions previously identiﬁed to comprise
FMDV 140S particles.
Disruption of 140S particles
Dissociation of 140S particles into 12S pentameric subunits was
performed by heat disruption. One hundred μl of puriﬁed A24
Cruzeiro or O1Campos 140S particles suspensions (1.6 ng/mL) were
heated at 60 1C during 20 min or left in ice for the same period.
Both heat-treated and non-treated samples were diluted in NET
buffer (0.1 M NaCl, 0.004 M EDTA, 0.05 M Tris pH 8.0) to a ﬁnal
volume of 4 ml and then 3.4 ml were overlayered in a 15–45% SDG
as described for virus puriﬁcation. Fractions collected from sucrose
gradients were analyzed by spectrophotometry at 260 nm and by
the antigen-ELISA described above. Fractions of the untreated and
heat-treated virus puriﬁed preparations (25 μg) were resolved in a
12% denaturing SDS-PAGE and proteins were stained by Coomassie
blue to study viral structural proteins integrity.
Statistical analyses
Statistical analyses were carried out using biostatistics, curve
ﬁtting and scientiﬁc graphing software (Statistix v8.0, Analytical
Software and GraphPad Prism v5.03,GraphPad Software). Signiﬁ-
cance was established within the 95% or 99% conﬁdence interval,
as indicated. To compare the tests accuracy in discriminating
between positive (PWM activated) and negative (PBS) samples,
receiver operator characteristic curves (ROC) were constructed
and tested for statistical signiﬁcance by Mann-Whitney non-
parametric test for independent samples. ROC curves were built
by plotting the corresponding Se and 1-Sp values at all possible
cut-off values to predict a dichotomous outcome (positive or
negative), considering the area under the curve (AUC) to deter-
mine the overall result of the test performance. The greater the
AUC, the better the test at predicting the outcome, considering all
possible combination of cut-off values (the null hypothesis was
AUC¼0.5). ROC curves, AUC values and conﬁdence interval, as well
as cut-off test values for maximization of accuracy in terms of Se
and Sp, were computed using ROCR package in R(Sing et al., 2005).
The Se and Sp of dichotomized test results was determined by the
optimal cut-off value in the ROC curves. Data is presented in a
scatter plot of the individual animal values and the protection
status between the conﬁdence interval selected as the criteria of
acceptance of values obtained by PBS and PWM treatment.
Comparison between mean values of two groups (i.e.: mean
concentration results against two viruses) was assessed by
unpaired non-parametric Mann-Whitney test. Comparison
between groups was performed by two way ANOVA followed by
Bonferroni (post-ANOVA).
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